Overview

Short Course: November 13
Conference: November 14-15

Real world evidence (RWE) is increasingly becoming important for regulatory decision-making and beginning to touch all areas of the healthcare value chain. Historically used for post-market safety monitoring, sponsors are now beginning to use RWE to support clinical trial design and observational studies in order to generate better treatment approaches, while healthcare systems are collecting and using RWE to substantiate coverage decisions. DIA’s Real World Evidence Conference will explore new and innovative applications of RWE, and deliver cutting-edge insights in how stakeholders are leveraging RWE to advance healthcare knowledge and decision-making.

Need approval in order to attend?

Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.

Preconference Short Course

Introduction to Real World Data for Data Geeks

Check out our 2019 Program!

Featured

Want to learn more about Real World Evidence Conference? You've come to the right site!

Who should attend?

Professionals involved in:

Learning objectives

At the conclusion of this activity, participants should be able to:

Discuss how RWE is being used today to inform biopharmaceutic development across product lifecycle
Describe the recent FDA strategic framework for RWD in regulatory decisions
Evaluate the future applications of RWE in drug development
Appraise how mobile technologies, AI, machine learning, and other technologies are being used to generate RWE
Evaluate how patient reported outcomes, EHR, and other patient data is expanding the resources for RWE
Discuss “lessons learned” from current uses of RWE, and how these can be applied for other future applications of RWE

Short Course or Primer

To keep you at the forefront.

Nov 13, 2019

Short Course:

Introduction to Real World Data for Data Geeks

Learn more

Nov 13, 2019

Short Course:

Introduction to Real World Data for Data Geeks

Learn more

Program Committee

Robert Suruki RWE Strategy Lead, Immunology
UCB Pharma, Inc., Belgium
Bart Barefoot, JD Head, Europe Regulatory Policy
GSK, United Kingdom
Brian Bradbury, DrSc, MA Vice President, Center for Observational Research
Amgen, United States
Paul M. Coplan, DrSc, MBA, MSc, FISPE VP, Medical Device Epidemiology & Real-World Data Analytics
Johnson & Johnson, United States
Jacqueline A. Corrigan-Curay, JD, MD Principal Deputy Center Director, Center for Drug Evaluation and Research (CDER)
FDA, United States
Nancy A Dreyer, PhD, MPH, FISPE Founder
Dreyer Strategies LLC, United States
Marni Hall, PhD, MPH VP & GM, Global Regulatory Science and Strategy
IQVIA, United States
James Harnett, PharmD, MS Executive Director, Health Economics and Outcomes Research
Regeneron Pharmaceuticals, Inc. , United States
Debra Schaumberg, DrSc, MPH Vice President and Global Head, Startegic Development Consulting Chair
Evidera | PPD, United States
Mark Stewart, PhD Vice President, Science Policy
Friends of Cancer Research, United States